Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
There is a growing body of evidence that the optimal adjuvant endocrine therapy for hormone-sensitive breast cancer in postmenopausal women should include an aromatase inhibitor. However, further research is required to establish the optimal aromatase inhibitor and whether such a drug should be used as monotherapy or in sequence after 2 to 3 years of tamoxifen.
St. George's Hospital, London, United Kingdom.
Giles
G
Cunnick
Kefah
K
Mokbel
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D004703:Endocrine System / Q000187:drug effects; D005260:Female; D006801:Humans; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000473:pathology; D017698:Postmenopause; D013629:Tamoxifen / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D013629:Tamoxifen